Jun. 11 at 12:29 PM
The attachment is a history of all 62 new commercial-stage oncology focused bios since 1/1/2013, and what would have happened to you if you invested
$1,000 in all 62 at the time of approval.
Had you invested
$1,000 in all 62 at the bio's closing share price the day after approval was announced, your
$62,000 investment would be worth
$60,008 today (excluding the time value of money).
As we've posted time & again, 18 of the 62 were sold @ gains & 9 of the 62 were sold at a loss (using the bio's closing share price 1 day post approval). Our summary makes 1 adjustment to reflect those commercial-stage bios sold within 2 years after FDA approval & those that waited for more than 2 years. The data speaks for itself.
The historical evidence is overwhelming, as is common sense, shareholder value of bios in this peer group is maximized via M&A exit within 2 years of FDA approval.
$GERN
$LEGN
$KPTI
$ADCT
$KURA